SCHEMBL2762234

SCHEMBL2762234

Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.57
MAOA P21397 5/20 0.57
MEN1 O00255 8/20 0.56
KMT2A Q03164 8/20 0.56
RAB9A P51151 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 3/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
POLB P06746 2/20 0.53
HSD11B1 P28845 4/20 0.52
HSD17B1 P14061 2/20 0.52
HSD17B2 P37059 2/20 0.52
MAPT P10636 2/20 0.52
PKM P14618 1/20 0.52
TDP1 Q9NUW8 1/20 0.50
SLC40A1 Q9NP59 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762614 0.89 KDM1A (0.69) KDM1AMAOAMEN1KMT2APOLB
SCHEMBL2762518 0.82 KDM1A (0.65) KDM1AMAOAMEN1KMT2APOLB
SCHEMBL2762719 0.82 KDM1A (0.66) KDM1AMAOAMEN1KMT2ARAB9A
SCHEMBL3936822 0.81 HSD11B1 (0.64) ALDH1A1SMN1; SMN2HSD11B1MAPTTDP1
SCHEMBL2762413 0.81 KDM1A (0.68) KDM1AMAOAMEN1KMT2ARAB9A
SCHEMBL2763006 0.80 KDM1A (0.61) KDM1AMAOAMEN1KMT2ARAB9A
SCHEMBL2762613 0.80 POLB (0.65) KDM1AMAOAMEN1KMT2APOLB
SCHEMBL2762412 0.80 HSD11B1 (0.54) KDM1AMAOAMEN1KMT2ARAB9A
SCHEMBL3625075 0.80 HSD11B1 (0.61) KDM1AMAOAMEN1KMT2ARAB9A
SCHEMBL2762432 0.80 MEN1 (0.58) KDM1AMAOAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KDM1A 1332/4885MAOA 335/4885MEN1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.